{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:27:27Z","timestamp":1762507647815},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.acuro.2018.08.005","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T15:57:49Z","timestamp":1548777469000},"page":"182-189","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Diez a\u00f1os de experiencia con el tratamiento multimodal de la fase aguda de la enfermedad de Peyronie: reporte m\u00e9dico de la vida real"],"prefix":"10.1016","volume":"43","author":[{"given":"L.","family":"Gallo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sarnacchiaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2018.08.005_bib0150","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","article-title":"The management of Peyronie's disease: Evidence-based 2010 guidelines","volume":"7","author":"Ralph","year":"2010","journal-title":"J Sex Med."},{"key":"10.1016\/j.acuro.2018.08.005_bib0155","doi-asserted-by":"crossref","first-page":"282503","DOI":"10.1155\/2011\/282503","article-title":"Population-based study of Peyronie's disease: Prevalence and treatment patterns in the United States","volume":"2011","author":"Dibenedetti","year":"2011","journal-title":"Adv Urol."},{"key":"10.1016\/j.acuro.2018.08.005_bib0160","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.ijir.3900877","article-title":"Clinical presentations of Peyronie's disease","volume":"14","author":"Pryor","year":"2002","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.acuro.2018.08.005_bib0165","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0022-5347(06)00270-9","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2018.08.005_bib0170","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.aju.2013.03.008","article-title":"Peyronie's disease: A contemporary review of non-surgical treatment","volume":"11","author":"Levine","year":"2013","journal-title":"Arab J Urol"},{"key":"10.1016\/j.acuro.2018.08.005_bib0175","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.urology.2016.02.009","article-title":"Contemporary review of treatment options for Peyronie's disease","volume":"95","author":"Sherer","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2018.08.005_bib0180","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1743-6109.2011.02519.x","article-title":"Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease","volume":"9","author":"Abern","year":"2012","journal-title":"J Sex Med"},{"key":"10.1016\/j.acuro.2018.08.005_bib0185","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1871528112666131205112432","article-title":"Long-term multimodal therapy (verapamil associated with propolis, blueberry, vitamin E and local diclofenac) on patients with Peyronie's disease (chronic inflammation of the tunica albuginea). Results of a controlled study","volume":"12","author":"Paulis","year":"2013","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.acuro.2018.08.005_bib0190","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/and.12178","article-title":"Combination of intralesional verapamil and oral antioxidants for Peyronie's disease: A prospective, randomised controlled study","volume":"46","author":"Favilla","year":"2014","journal-title":"Andrologia"},{"key":"10.1016\/j.acuro.2018.08.005_bib0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5539\/gjhs.v6n7p23","article-title":"Evaluation of verapamil efficacy in Peyronie's disease comparing with pentoxifylline","volume":"6","author":"Alizadeh","year":"2014","journal-title":"Glob J Health Sci."},{"key":"10.1016\/j.acuro.2018.08.005_bib0200","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4103\/0974-7796.152048","article-title":"Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie's disease","volume":"7","author":"Dell\u2019Atti","year":"2015","journal-title":"Urol Ann."},{"key":"10.1016\/j.acuro.2018.08.005_bib0205","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.juro.2015.03.092","article-title":"The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie's disease","volume":"194","author":"Yafi","year":"2015","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2018.08.005_bib0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1745-7262.2008.00351.x","article-title":"Non-surgical therapy of Peyronie's disease","volume":"10","author":"Taylor","year":"2008","journal-title":"Asian J Androl"},{"key":"10.1016\/j.acuro.2018.08.005_bib0215","first-page":"30","article-title":"Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells","volume":"76","author":"Schanden\u00e9","year":"1992","journal-title":"Immunology"},{"key":"10.1016\/j.acuro.2018.08.005_bib0220","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/gut.50.2.241","article-title":"Pentoxifylline downregulates profibrogenic cytokines and procollagen i expression in rat secondary biliary fibrosis","volume":"50","author":"Raetsch","year":"2002","journal-title":"Gut."},{"key":"10.1016\/j.acuro.2018.08.005_bib0225","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1464-410X.2009.09041.x","article-title":"A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease","volume":"106","author":"Safarinejad","year":"2010","journal-title":"BJU Int."},{"key":"10.1016\/j.acuro.2018.08.005_bib0230","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/aja.2010.117","article-title":"Pentoxifylline treatment and penile calcifications in men with Peyronie's disease","volume":"13","author":"Smith","year":"2011","journal-title":"Asian J Androl."},{"key":"10.1016\/j.acuro.2018.08.005_bib0235","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.niox.2003.12.002","article-title":"L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures","volume":"9","author":"Valente","year":"2003","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.acuro.2018.08.005_bib0240","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1073\/pnas.93.11.5478","article-title":"Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix","volume":"93","author":"Roth","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.acuro.2018.08.005_bib0245","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/sj.ijir.3900874","article-title":"Peyronie's disease cell culture models: Phenotypic, genotypic and functional analyses","volume":"14","author":"Mulhall","year":"2002","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.acuro.2018.08.005_bib0250","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0022-5347(17)35291-6","article-title":"Intralesional verapamil injection for the treatment of Peyronie's disease","volume":"151","author":"Levine","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2018.08.005_bib0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ijir.2011.45","article-title":"Review of non-surgical treatment options for Peyronie's disease","volume":"24","author":"Larsen","year":"2012","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.acuro.2018.08.005_bib0260","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1743-6109.2008.00814.x","article-title":"Penile traction therapy for treatment of Peyronie's disease: A single-center pilot study","volume":"5","author":"Levine","year":"2008","journal-title":"J Sex Med."},{"key":"10.1016\/j.acuro.2018.08.005_bib0265","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/jsm.12400","article-title":"Acute phase Peyronie's disease management with traction device: A nonrandomized prospective controlled trial with ultrasound correlation","volume":"11","author":"Mart\u00ednez-Salamanca","year":"2014","journal-title":"J Sex Med."},{"key":"10.1016\/j.acuro.2018.08.005_bib0270","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.urology.2015.03.010","article-title":"Intralesional injections for early Peyronie disease: Standardized assessment and analysis of predictive factors for treatment response","volume":"86","author":"Wolff","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2018.08.005_bib0275","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0022-5347(05)64691-5","article-title":"Experience with intraplaque injection of verapamil for Peyronie's disease","volume":"168","author":"Levine","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.acuro.2018.08.005_bib0280","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","article-title":"Use of intralesional verapamil to dissolve Peyronie's disease plaque: A long-term single-blind study","volume":"51","author":"Rehman","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2018.08.005_bib0285","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie's disease: A randomized single-blind, placebo-controlled study","volume":"41","author":"Shirazi","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.acuro.2018.08.005_bib0290","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1111\/j.1743-6109.2009.01662.x","article-title":"Effect of penile-extender device in increasing penile size in men with shortened penis: Preliminary results","volume":"8","author":"Nikoobakht","year":"2011","journal-title":"J Sex Med."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480618302821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480618302821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T02:50:53Z","timestamp":1662864653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480618302821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0210480618302821"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2018.08.005","relation":{},"ISSN":["0210-4806"],"issn-type":[{"value":"0210-4806","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diez a\u00f1os de experiencia con el tratamiento multimodal de la fase aguda de la enfermedad de Peyronie: reporte m\u00e9dico de la vida real","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2018.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}